NCT07237373 Percutaneous Thermo-ablation for the Treatment of Benign Thyroid Nodules
| NCT ID | NCT07237373 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Ghent |
| Condition | Benign Thyroid Nodule |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-03-03 |
| Primary Completion | 2030-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2026-03-03 with a primary completion date of 2030-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn if radiofrequency ablation (RFA), a minimally invasive thermoablation technique, can safely reduce symptoms and improve quality of life in adults with symptomatic benign thyroid nodules or autonomously functioning thyroid nodules. The main questions it aims to answer are: * Does RFA improve health-related quality of life (HRQoL) as measured by the ThyPRO-39 questionnaire? * Does RFA effectively reduce nodule volume and related symptoms (compressive or cosmetic)? Participants will: * Undergo a radiofrequency ablation procedure of the thyroid nodule performed under ultrasound guidance in an outpatient setting. * Complete quality of life questionnaires (ThyPRO-39) before treatment and at follow-up visits. Attend follow-up visits at 1, 3, 6, and 12 months with: * Ultrasound assessments of the thyroid nodule * Symptom and cosmetic scoring * Blood tests to monitor thyroid function * Safety checks for possible complications
Eligibility Criteria
Inclusion Criteria: * \> 18 years old * 'Eastern Cooperative Oncology Group' (ECOG) performance status of 0 or 1 * Symptomatic benign thyroid nodules with compressive/cosmetic complaints OR autonomously functioning thyroid nodules with subclinical hyperthyreosis or thyrotoxicosis proven on scintigraphy. * No cutoff in nodule size. * Solid component \> 20%, and benign cytology (Bethesda II) in 1 (EUTIRADS 3) or 2 (EUTIRADS 4) separate cytological assessments. In the case of a proven "hot" nodule on scintigraphy, no biopsy is required. Exclusion Criteria: * \<18y * Purely cystic nodule * Severe comorbidity which limits the further life expectancy of the patient to \< 2 years (opinion of the physician) * Malignancies \<2 years ago except for non-melanoma skin cancer and non-muscle invasive bladder cancer. * Lack of compliance * Malignant or suspicious thyroid nodules or nodules that are confluent in a compressive lobar mass * Contralateral vocal cord paralysis * Anticoagulant therapy that could not be suspended * Unresolvable coagulation disorders * Absence of consent of the patient
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07237373 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Benign Thyroid Nodule. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07237373 currently recruiting?
Yes, NCT07237373 is actively recruiting participants. Contact the research team at studies.vinrad@uzgent.be for enrollment information.
Where is the NCT07237373 trial being conducted?
This trial is being conducted at Bruges, Belgium, Ghent, Belgium, Leuven, Belgium.
Who is sponsoring the NCT07237373 clinical trial?
NCT07237373 is sponsored by University Hospital, Ghent. The trial plans to enroll 50 participants.